higher restenosis rate. 8 Based on a cost-effectiveness analysis, the recent BASKET study proposed that DES should not be used in all patients, only in selected patients. 16 Longterm safety, efficacy and cost concerns highlight the need to continue to explore alternative strategies for reducing the occurrence of restenosis.
The cutting balloon is a unique device that consists of a balloon catheter with 3-4 blades or atherotomes that create longitudinal incisions in the atherosclerotic lesion during balloon inflation. Although a previous multicenter study of the use of cutting balloon angioplasty (CBA) without stent implantation or intravascular ultrasound (IVUS) guidance failed to show a long-term advantage of CBA over balloon angioplasty (BA), 17 another study has indicated some clinical benefit. 18 The use of IVUS guidance and stent implantation could be essential for obtaining optimal results with PCI using CBA.
We hypothesized that CBA prior to bare metal stent (BMS) would assist in achieving full stent expansion with safety and improve accommodation of reactive intimal hyperplasia, thereby producing a favourable long-term outcome.
To test this hypothesis, we performed a prospective, randomized, multicenter trial to compare CBA with BA before stenting in 521 patients with and without IVUS guidancethe Restenosis Reduction by Cutting Balloon Angioplasty Evaluation (REDUCE III) study.
Methods

Study Design
The REDUCE III trial was designed as a prospective, multicenter, randomized study to compare CBA before BMS implantation and BA prior to stenting. Five hundred and twenty-one patients were randomly assigned to either CBA prior to stenting or BA before stenting in an envelope manner at 38 participating centers. To ensure an equal distribution of both treatments per center, the randomization sequence was developed on a site basis. IVUS-guided procedures (pre and post) and follow-up were performed in 22 centers and angiographic-guided procedures were done in the remaining 16. IVUS-guided procedures were performed in 279 (54%) patients, and angiographic-guided procedures were done in the remaining 242 (46%) patients.
Study Endpoints
The primary endpoint of this study was angiographic restenosis (defined as ≥50% diameter stenosis at follow-up by quantitative coronary angiography (QCA)) and subsequent target lesion revascularization (TLR) at follow-up. The principal clinical endpoint was a composite of MACE, including SAT (≤30 days after the procedure), LST (>30 days after the procedure), death, Q-wave and non-Q-wave myocardial infarction, and need for TLR. [7] [8] [9] 19, 20 
Patient Selection
Patients with unstable or stable angina, a single target lesion in a native coronary artery with a vessel diameter less than 4 mm, and planned stent implantation with up to 2 stents and agreement to follow-up angiography were included. Patients were excluded from the study if they had (1) contraindication to anticoagulation and antiplatelet therapy; (2) graft disease; or (3) left main coronary artery disease. The study was approved by the local ethics committees and was carried out according to the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all patients.
PCI Procedures
CBA and BA prior to stent implantation were performed according to standard clinical practice with radial or femoral approaches using guide catheters 6F or greater in size to facilitate subsequent QCA analysis. 19, 20 A bolus of 8,000-10,000 IU of heparin (repeated if necessary) was administrated during the procedure, followed by combination antiplatelet therapy. 19 According to standard patient care, treatment with aspirin at a dose of 100-300 mg/day was started before the procedure and continued indefinitely, and treatment with ticlopidine at 200 mg/day was begun before or immediately after the procedure and continued for at least 2 weeks. Although BMS, including the NIR stent (Boston Scientific Co, Freemont, CA, USA) or Multilink stent (Guidant, Santa Clara, CA, USA), were recommended for use, the use of other types of BMS was left to the operator's discretion. However, no DES were used in the REDUCE III study.
IVUS-Guided and Angiographic-Guided Procedures
CBA, BA and stent sizes were determined by angiographic reference vessel diameter (RD) in the angiographyguided group, and by vessel dimension and plaque distribution detected by IVUS in the IVUS-guided group. The angiographic criteria for optimal stenting were a residual stenosis less than 30% and no flow limiting dissection. 19 The IVUS criteria for optimal stenting were the common criteria originally derived from the MUSIC study: (1) good stent apposition with symmetric stent expansion; (2) full stent expansion with sufficient lumen area (LA) in the lesion segment (ie, LA 80% or greater of the average reference LA pre-intervention); and (3) the absence of major dissection. 20 To fulfill these criteria, high-pressure intra-stent balloon inflation or additional stenting was performed. High-pressure intra-stent balloon inflation was done using conventional balloons (ie, stent balloon or greater sized balloon).
IVUS
Following selective coronary angiography after the intracoronary injection of nitrates, a mechanical intracoronary ultrasound imaging catheter (40-MHz, 2.5 Fr or 2.9 Fr, Boston Scientific Co, Fremont, CA, USA) was introduced over a 0.014-inch guidewire before, immediately after CBA or BA, after stenting, and at follow-up. 21, 22 After the imaging catheter was passed into and beyond the lesion, a motorized pullback was started to obtain an assessment of the target lesion. IVUS images were stored on super VHS videotape for off-line analysis. 21 
Quantitative IVUS Assessment
Serial IVUS analysis pre-procedure, immediately after CBA or BA, post-stenting and at 7-month follow-up was performed at an independent core laboratory of Aichi Medical University and Fujita Health University. Crosssectional luminal area was defined as the integrated area central to the intimal leading edge echo. 21 The total vessel cross-sectional area (VA) was defined as the area inside the interface between the plaque -media complex and adventitia (area inside the external elastic membrane). 21, 23 VA, LA and plaque area were measured by the image analysis computer (Tapemeasure, Index Systems, Mountain View, CA, USA). 21, 24 The lesion segment was determined from pre-intervention images, including the frame with the smallest LA, whereas the proximal and distal reference segments were defined as the location of the least amount of disease before the emergence of any major side branches. The corresponding frames at post-intervention and follow-up were determined by using peri-and intracoronary landmarks such as calcium deposits, side branches and venous structures. 21 
QCA
QCA analyses were performed using the computer-based edge-detection coronary angiography analysis system (CAAS II, Pie Medical, Maastricht, Netherlands). [19] [20] [21] [25] [26] [27] Coronary angiograms were obtained in multiple views matched after the intracoronary injection of nitrates. Interpolated RD, minimal lumen diameter (MLD) and percent diameter stenosis were obtained at baseline (pre-), post-stenting and at follow-up using the guiding catheter as a scaling device. [19] [20] [21] [25] [26] [27] QCA measurements and subsequent QCA subanalysis were performed at an independent core laboratory of the Aichi Medical University and Fujita Health University. Restenosis was defined as ≥50% diameter stenosis at follow-up.
Statistical Analysis
Data were analyzed using the SAS statistical software package (SAS Institute, Cary, NC, USA). All continuous values are expressed as mean ± SD. Differences in categorical variables were assessed using the chi-square test and Fisher's exact test. The unpaired t-test was used to assess differences in continuous variables between 2 groups and ANOVA for 4 groups. Where a significant difference was detected by ANOVA, multiple comparison analysis was performed to disclose where the significance existed among the 4 values. 28 All data were analyzed on an intention-to-treat basis. A 2-tailed value of p<0.05 was considered significant.
Results
Patient and Lesion Characteristics
Five hundred and twenty-one patients entered the study, of which 260 were randomized to CBA before bare metal stenting and 261 to BA prior to BMS implantation. The 2 groups were well matched without significant differences in baseline clinical and demographic characteristics (Table 1) . Target coronary artery was similar between the 2 groups. Although no difference was seen in the American College Cardiology -American Heart Association lesion classification between the 2, the majority of the lesions were complex in both groups (type B2/C in CBA with BMS; 61.9%, type B2/C in BA with BMS; 65.2%).
CBA, BA and Stent Implantation
Although balloon size prior to stenting was similar between the 2 groups, the inflated pressure was significantly lower with CBA than BA because of the limitation of maximal inflated pressure allowed with CBA (Table 1) .
Of the 260 patients randomized to CBA with stenting, 4 did not undergo CBA because of failure to cross the lesion, but they were successfully treated with BA (CBA success (Table 1) .
QCA Results
The overall angiographic follow-up rate was 87% (453 of 521 patients), with a mean angiographic follow-up period of 6.9 months. No significant difference was found in the angiographic follow-up rate, baseline reference vessel size (RD-pre), MLD pre-procedure (MLD-pre) and lesion length between the 2 groups ( Table 2) . MLD-post procedure was significantly greater for CBA-BMS than BA-BMS (p= 0.002) and was associated with significantly less residual diameter stenosis in the CBA-BMS group than in the BA-BMS group (p=0.001) ( Table 2 ). This favorable effect for the CBA-BMS strategy carried over to follow-up. The residual diameter stenosis at follow-up was significantly less for CBA-BMS than for BA-BMS (p=0.039) ( Table 2 ). The difference in residual diameter stenosis at follow-up subsequently conferred a significant difference in the restenosis rate.
However, no significant difference was observed in the restenosis rate between the different stent types in the 453 patients with follow-up angiography (NIR: 18.4%, Multilink: 11.9%, others: 17.6%, p=0.183) or in each group (CBA-BMS: NIR 13.4%, Multilink 8.7%, others 17.6%, p=0.424; BA-BMS: NIR 23.5%, Multilink 15.1%, others 17.6%, p=0.306).
IVUS Results
To achieve optimal stent implantation in the IVUSguided groups (IVUS-guided CBA-BMS and IVUS-guided BA-BMS), high-pressure intra-stent balloon inflations or additional stent implantations were performed in 108 of 137 patients (78.8%) undergoing IVUS-CBA-BMS and in 117 of 142 patients (82.3%) having IVUS-BA-BMS (p= 0.451). High-pressure intra-stent balloon inflations were done using either stent balloons or larger conventional balloons. IVUS core laboratory off-line analysis revealed that at least 1 of 3 optimal stenting criteria was not reached in 19 of 137 patients (13.9%) in the IVUS-guided CBA and BMS group and in 34 of 142 patients (23.9%) in the IVUS guided BA and BMS group (p=0.031). Serial (pre, post and follow-up) IVUS was obtained in 141 patients (IVUS-CBA-BMS; 71 patients, IVUS-BA-BMS: 70 patients). Although baseline VA and LA in the lesion segment were similar in the IVUS-guided CBA-stent and the IVUS-guided BA-stent groups, LA immediately after CBA was significantly greater than LA following BA (5.3± 1.6 mm 2 vs 4.1±1.3 mm 2 , p=0.019) ( Table 2 ). This favorable greater LA in the lesion segment achieved by IVUS-guided CBA than by IVUS-guided BA carried over after stenting (7.4±2.2 mm 2 vs 6.0±2.0 mm 2 , p=0.035) and subsequently at follow-up (5.3±2.8 mm 2 vs 4.4±2.0 mm 2 , p=0.043) ( Table 2) .
Clinical Outcomes
Clinical follow-up was obtained in all 521 patients (100%). In the CBA with BMS group 1 patient was lost to angiographic follow-up and died of a ventricular arrhythmia 12 months after the procedure, and 2 patients experienced procedure-related acute myocardial infarction (Table 3) . TLR was done by PCI in 25 (9.6%) patients, and PCI at follow-up was done for newly developed lesions in different vessels from the target vessels in 2 (0.8%) patients in the CBA-BMS group (Table 3) . The event-free survival was therefore 88.5% at follow-up.
In the BA with BMS group, 1 patient experienced SAT with myocardial infarction 4 days after the procedure but underwent emergency PCI and Thrombolysis in Myocardial Infarction III flow was quickly restored (Table 3) . One patient died of heart failure 4 months after the procedure (cardiac death) and 1 without follow-up angiography died of lung cancer 12 months after the procedure (non-cardiac death). A further 39 (14.9%) patients had TLR by PCI, and 1 (0.4%) underwent coronary artery bypass grafting. The event-free survival per patient was therefore 83.9% at follow-up. Late thrombosis was not observed in any group after the procedure.
The TLR rate was significantly lower in the CBA-BMS group than in the BA-BMS group (p=0.048). The incidence of MACE tended to be lower for CBA-BMS but this trend did not reach statistical significance (p=0.082) ( Table 3) .
Comparison of Restenosis Rate Among the 4 Groups
Of the 260 patients with CBA and BMS, 137 patients underwent CBA and BMS under IVUS-guidance (IVUS-CBA-BMS) and 123 under angiographic-guidance alone (Table 4) . No difference was found in the angiographic follow-up rate, baseline RD-pre, MLD-pre or lesion length between the 4 groups ( Table 4) . MLD-post procedure was significantly greater in the IVUS-CBA-BMS group compared with Angio-CBA-BMS, IVUS-BA-BMS and Angio-BA-BMS (p=0.001 by ANOVA, p<0.05 by multiple comparisons respectively) and the group had significantly less residual diameter stenosis than the other groups (p=0.001 by ANOVA) (Table 4 ). This favorable effect produced by the IVUS-CBA-BMS strategy carried over to follow-up. The residual diameter stenosis at follow-up was significantly less in the IVUS-CBA-BMS group than in the others (p=0.016 by ANOVA) (Table 4) . Similarly, a significant difference was observed following multiple comparison analysis between IVUS-CBA-BMS and IVUS-BA-BMS (p<0.05) and between IVUS-CBA-BMS and Angio-BA-BMS (p<0.05) ( Table 4) . The difference in residual diameter stenosis at follow-up subsequently conferred a significant difference in restenosis rates. The restenosis rate in the IVUS-guided CBA with stent group (6.6%; 8 of 122 patients) was lower than that in the angiographic-guided CBA with stent groups (17.9%; 19 of 106 patients); the IVUS-guided BA with stent group (19.8%; 25 of 126 patients); and that in angiographicguided BA with stent group (18.2%; 18 of 99 patients, p=0.016) ( Table 4 ). The favorable outcome for the CBA-BMS group (ie, combined IVUS-CBA-BMS and Angio-CBA-BMS groups) was mainly conveyed by the low restenosis rate produced by the IVUS-guided-CBA-BMS strategy (restenosis rate: 6.6%).
Multivariate Analysis Results
Multivariate analyses to evaluate the respective contributions of the clinical, angiographic and IVUS variables to restenosis indicated that the use of BA (but not of CBA), smaller vessel area on IVUS, diabetes, left anterior descending (LAD) lesion and total stent length were independent predictors for stent restenosis at follow-up (Table 5) . Minimal LA post stenting by IVUS tended to be a significant (p=0.072) but not a significant independent predictor.
Discussion
This prospective multicenter randomized study (REDUCE III) has demonstrated that using a CBA strategy prior to BMS implantation could provide significantly greater MLD-post (p=0.002) with less residual percentage diameter stenosis post procedure (p=0.001) than BA with BMS (Table 2 ). This strategy subsequently resulted in significantly less percentage diameter stenosis at follow-up (p= 0.039), conferring a substantially lower restenosis rate and lower incidence of TLR than in the BA with BMS group (Tables 2,3 ). The greater lumen diameter obtained by an IVUS-guided CBA strategy could have contributed to the favorable long-term outcomes observed. Multivariate analysis indicated that the use of BA, but not CBA, small vessels, diabetes, LAD lesion location and longer stent length were independent predictors for restenosis at followup.
Role of IVUS Guidance in CBA and BA Prior to BMS
Previous studies investigating the benefit of an IVUSguided PCI strategy have yielded conflicting evidence. Although Fitzgerald et al 24 found that IVUS-guided stenting resulted in more effective stent expansion and subsequently a lower restenosis rate in comparison with angiographic guidance alone, Mudra et al reported that optimizing stent implantation by IVUS failed to show beneficial effects on long-term outcome. 29 The latter suggested that those with extensive experience with IVUS obtained similar final results to those not using IVUS guidance. More recently however, Oemrawsingh et al revealed that angiographic and clinical outcome after stenting for long lesions guided by IVUS is superior to that performed using angiography alone. 30 Our REDUCE III study results indicate that despite similar vessel size and lesion severity, IVUS-guided CBA with BMS produced significantly greater MLD-post (p=0.001) with less residual percentage diameter stenosis-post (p= 0.001) and resulted in significantly less percentage diameter stenosis at follow-up (p=0.016), as well as a lower restenosis rate (p=0.016) ( Table 4) . Without IVUS guidance, the interventional operator systematically tends to select undersized devices because of fears about the inherent danger of vessel perforation. This may negate the benefits of CBA and result in a suboptimal smaller LA similar to that which might be achieved with BA alone.
However, we did not have an IVUS blinded arm (IVUS playing a spectator role), unlike the CRUISE study. 24 Therefore, all the information provided by IVUS could have affected the subsequent PCI procedure for both IVUSguided CBA-BMS and IVUS-guided BA-BMS. We speculate that IVUS-guidance CBA facilitated the use of larger cutting balloon sizes and gave the operator increased confidence and latitude with balloon sizing. This favourable effect of IVUS could play a more important role in CBA rather than with simple BA. IVUS-guided CBA would have minimized vessel injury and risk of complications while maximising the achieved MLD.
Impact of the IVUS-Guided CBA-BMS Strategy in the Era of DES
Our REDUCE III study has demonstrated that the use of an IVUS-guided CBA strategy prior to stent implantation can achieve acceptably low restenosis rates (6.6%) that are comparable to those achieved with DES (Table 4) . Although the First experience In Man and the RAVEL studies indicated complete inhibition of restenosis, the broader application of DES in the SIRIUS and TAXUS-IV studies demonstrated that they markedly reduced but did not eliminate the problem of restenosis. [7] [8] [9] 11, 12 Substantial growth in the real-life clinical use of DES has revealed some potentially significant limitations. A recent US FDA public health notification, including data from the RADAR project, has warned that the occurrence of SAT, LST and hypersensitivity reactions to sirolimus may have significantly contributed to serious adverse cardiac events experienced by some patients. 2, 6, 15 Both subacute and LST have been associated with non-fatal myocardial infarction or death. [2] [3] [4] [5] [6] 14, 15, 31 Recently, Iakovou et al reported that subacute and LST occurred in 29 of 2,229 patients (1.3%) and the incidence in "real-world" patients was substantially higher than the rate reported in clinical trials. 4 Furthermore, Rodriguez et al revealed that stent thrombosis occurred in 7 (3.1%) of 225 patients following DES and 4 (1.8%) of them had LST. 6 In the present study, SAT occurred in 1 patient in the angiographic-guided BA and BMS group and LST was not observed in any patient. Longterm safety data beyond 5 years have not yet been available for DES, whereas conventional stent use has a history spanning nearly 2 decades. Therefore, until long-term safety concerns have been allayed, there remains a need to explore alternative strategies for improving the outcomes achieved with conventional stent technologies.
Independent Predictors for Stent Restenosis
Several independent predictive factors for restenosis have been proposed from muticenter randomized studies or large sample studies. [32] [33] [34] [35] Although Kastrati et al revealed that diabetes, small MLD-post and multiple stents were predictors for stent restenosis, de Feyter et al indicated that MLD area on IVUS and stent length were independent predictors for stent restenosis. 32, 33 Kasaoka et al showed that longer stent length, smaller vessel size, MLD-post and post stent LA on IVUS were strong predictors for stent restenosis, 34 but Carrozza et al disclosed that stenting of the LAD was the strongest predictor of restenosis in their multivariate model. 35 We initially used multivariate analysis to examine the clinical, angiographic and IVUS predictors for restenosis in patients undergoing CBA and BA prior to BMS, and our multivariate model clearly demonstrated that the use of BA (but not of CBA) was the strong independent predictor for restenosis, in addition to conventional restenosis predictors such as small vessels, diabetes, LAD lesion location and longer stent length. The importance of using CBA, but not BA, prior to stenting on the reduction of stent restenosis were reconfirmed by both univariate analysis and the multivariate model.
Study Limitations
First, we successfully reached the primary endpoints (ie, angiographic restenosis, as well as TLR), but we could not show a statistical difference in MACE, even though the incidence of MACE tended to be lower for CBA with BMS (11.5%) than for BA with BMS (16.8%, p=0.082).
Second, we did not perform a direct comparison of IVUS-guided CBA-BMS and DES. A prospective randomized study including a DES arm with a greater overall sample size is required to confirm whether the IVUS guided CBA-BMS strategy can really provide a similar clinical outcome to that for DES.
Conclusions
Despite tackling complex lesion morphology (ie, 62% of the lesions were type B2/C) in relatively small vessels (average size: 2.82 mm), this prospective multicenter randomized study (REDUCE III) clearly demonstrated that the use of CBA prior to BMS had a high procedural success rate (98%), with favorable event-free survival (88.5%) and significantly lower rates of restenosis and TLR for CBA-BMS than for those undergoing BA-BMS. This favorable outcome in the CBA-BMS arm was mainly derived from the IVUS-guided CBA-BMS strategy, low restenosis rates (6.6%) comparable to those achieved in recent DES studies.
